A multinational research team led by Professor Małgorzata Kujawska at Poznań University of Medical Sciences has found that graphene quantum dots (GQDs) can counteract the clumping of α-synuclein (ASN), a protein whose aggregation is a hallmark of synucleinopathies including Parkinson's disease and multiple system atrophy (MSA). The study, published in Science and Technology of Advanced Materials (STAM), details how these nanoscale carbon particles interfere with the formation of toxic protein fibers.
Current treatments for synucleinopathies only manage symptoms rather than halting the underlying protein clumping, which leads to progressive neuronal loss. The research team tested GQDs in cell-free environments, neuronal cultures, and animal models of MSA. When administered intranasally in mice, GQDs significantly reduced the presence of toxic ASN aggregates. The treatment also appeared to activate autophagy, a cellular recycling process that helps break down and remove damaged proteins.
“This study points to a promising new direction for strategies against neurodegenerative diseases,” says Professor Kujawska. “While clinical use of GQDs remains a long way off, these findings strengthen the case for further research.” At concentrations relevant to its biological effects, the GQD showed a favorable safety profile, though some changes in cellular stress and immune responses were observed at higher doses.
Challenges remain, such as preventing quantum dots from clumping in liquid suspensions. “GQDs may serve as a useful research tool,” says Professor Kujawska. “What we learn as we optimize their properties and conduct a comprehensive safety evaluation could help design more effective nanomaterial-based strategies not just for synucleinopathies, but also for other conditions characterized by the buildup of toxic proteins.”
